MS-444
Based on 4 publication(s) in Google Scholar
MS-444 (BE-34776) is a HuR (ELAVL1) inhibitor that blocks the cytoplasmic translocation of HuR and inhibits its dimerization. MS-444 reduces cytoplasmic HuR levels by preventing the binding of HuR to ARE-mRNA, without altering the total expression of HuR. MS-444 induces apoptosis, inhibits cell growth, angiogenesis and invasion, and also regulates immune function and microbiota. MS-444 effectively alters the number, size and invasiveness of tumors in various cancer models. MS-444 is tolerable to intraperitoneal injection in vivo and can be applied to research related to colorectal cancer, familial adenomatous polyposis, colitis-associated cancer and glioblastoma.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 98.75%
- CAS No.: 150045-18-4
- 화학식: C13H10O4
- 분자량:230.22
-
보관:
-20°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Publications Citing Use of MedChemExpress (MCE) MS-444
More
Biological Activity
제품 설명
IC50 & Target
|
COX-2 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Monocyte | IC50 |
2.1 μM
Compound: 2, MS-444
|
Inhibition of COX-2 gene expression in LPS/INF-gamma-stimulated human primary monocytes by RT-PCR analysis
Inhibition of COX-2 gene expression in LPS/INF-gamma-stimulated human primary monocytes by RT-PCR analysis
|
[PMID: 17632515] |
| Monocyte | IC50 |
2.4 μM
Compound: 2, MS-444
|
Inhibition of IL-6 gene expression in LPS/INF-gamma-stimulated human primary monocytes by RT-PCR analysis
Inhibition of IL-6 gene expression in LPS/INF-gamma-stimulated human primary monocytes by RT-PCR analysis
|
[PMID: 17632515] |
| Monocyte | IC50 |
3.7 μM
Compound: 2, MS-444
|
Inhibition of IL1-beta gene expression in LPS/INF-gamma-stimulated human primary monocytes by RT-PCR analysis
Inhibition of IL1-beta gene expression in LPS/INF-gamma-stimulated human primary monocytes by RT-PCR analysis
|
[PMID: 17632515] |
In Vitro
MS-444 (1-40.70 μM; 48 h) inhibits growth of HCT116, HCA-7, RKO, HT-29, and SW480 CRC cells with IC50 values ranging from 5.60 μM to 14.21 μM after 48 h, while non-transformed RIE-1 and YAMC intestinal cells are ~3- to 4-fold less sensitive with IC50 values of 40.70 μM and 28.16 μM, respectively[1].
MS-444 (10 μM; 48 h) induces apoptotic nuclear morphology in RKO, HCA-7, and HCT116 CRC cells after 48 h, but has no effect on non-transformed RIE-1 intestinal cells[1].
MS-444 (10 μM; 8 h) promotes nuclear localization of HuR in Ras-transformed RIE-iRas and YAMC-Ras intestinal cells after 8 h, while non-transformed RIE-1 and YAMC cells show no change in HuR localization[1].
MS-444 (1.5-25 μM; 8 h) inhibits COX-2 mRNA expression in HCA-7 CRC cells with an IC50 of 6.75 μM and reduces COX-2 protein levels in a dose-dependent manner after 8 h of treatment[1].
MS-444 (50 μM) reduces LPS-induced IL18 mRNA expression in RAW 264.7 wild-type macrophages[2].
MS-444 (5-80 μM; 24 h) dose-dependently inhibits invasion of JX12, U87, and U251 human glioblastoma cells and JX12 CD133+ BTICs in a matrigel transwell model, with maximal suppression at 20-80 μM depending on the cell type[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:colorectal cancer (CRC) cell lines (HCT116, HCA-7, RKO, HT-29, SW480), non-transformed intestinal epithelial cell lines (RIE-1, YAMC)
-
Concentration:1-40.70 μM
-
Incubation Time:48 h
-
Result:Inhibited growth in all CRC cell lines with IC50 values of 5.60 μM (RKO), 12.84 μM (HCA-7), 10.98 μM (HCT116), 14.21 μM (HT-29), and 10.98 μM (SW480).
Reduced growth of non-transformed RIE-1 and YAMC cells with IC50 values of 40.70 μM and 28.16 μM, respectively (P < 0.05).
Caused observable growth inhibition at 10 μM in CRC cells.
-
Cell Line:human glioblastoma xenolines (JX12 parent, CD133+ BTICs), U87 glioma cell line, U251 glioma cell line
-
Concentration:5, 10, 20 µM (JX12 parent and CD133+ BTICs); 10, 20, 40, 80 µM (U87 and U251 cells)
-
Incubation Time:24 h
-
Result:Significantly inhibited invasion in all tested glioblastoma cells at sub-lethal doses.
Reduced invading JX12 parent cells by 95% at 20 µM.
Reduced invading CD133+ BTICs by 80% at 10 µM.
Reduced invading U87 cells by 80-90% at 80 µM.
Showed dose-dependent attenuation of invasion in U251 cells, with maximal reduction at 40 µM.
Inhibited invasion at shorter 6 and 12 h treatment intervals, confirming effects were not due to cell death.
In Vivo
MS-444 (25 mg/kg; i.p.; every 48 hr) significantly inhibits HCA-7 colorectal cancer xenograft tumor growth in athymic nude mice and reduces tumor COX-2 protein expression[1].
MS-444 (25 mg/kg; i.p.; every 72 hr for 15 days then daily for 7 days) significantly reduces established HCA-7 colorectal cancer xenograft tumor volume and COX-2 expression in athymic nude mice[1].
MS-444 (10 mg/kg; i.p.; biweekly; duration of AOM/DSS treatment cycles) increases colorectal tumor burden, size, and invasiveness in AOM/DSS-induced colorectal cancer mice, while reducing tumor cell apoptosis, serum IL18 levels, and tumor-infiltrating eosinophils[2].
MS-444 (10 mg/kg; i.p.; biweekly; 9 weeks) reduces total and small intestinal tumor numbers in APCMin mice, while altering the fecal microbiota composition and restoring spleen architecture[2].
MS-444 (10-25 mg/kg; i.p.; biweekly) promotes epithelial regeneration in acute DSS-induced colitis in mice at 10 mg/kg, while higher doses exacerbate epithelial damage[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Athymic nude (Nu/Nu)[1]
-
Dosage:25 mg/kg
-
Administration:i.p.; every 72 hr for 15 days, then daily for 7 days
-
Result:Showed no significant tumor volume change until daily dosing began on day 14.
Reduced tumor volume significantly compared to controls by day 21.
Reduced COX-2 protein expression observed via ex vivo fluorescence imaging.
Reduced COX-2 mRNA expression significantly confirmed by qPCR.
-
Animal Model:C57BL/6J (3% DSS-induced)[2]
-
Dosage:10 mg/kg; 25 mg/kg
-
Administration:i.p.; biweekly
-
Result:Resulted in only 9% loss of the epithelial lining (compared to higher loss in controls and 24% loss with 25 mg/kg MS-444) at 10 mg/kg dose.
Promoted epithelial regeneration at 10 mg/kg dose.
Shifted HuR from the nucleus to the cytoplasm in intestinal tissue in a dose-dependent manner.
Exacerbated epithelial damage at 25 mg/kg dose.
Chemical Information
-
CAS No. 150045-18-4
-
Appearance Solid
-
분자량 230.22
-
화학식 C13H10O4
-
Color Light yellow to brown
-
SMILES
O=C(C1=C(C)OC=C1C2)C3=C2C(O)=CC=C3O
-
Synonyms
BE-34776
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
-20°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
EMBO J
RNA-binding proteins hnRNPM and ELAVL1 promote type-I interferon induction downstream of the nucleic acid sensors cGAS and RIG-I. [Abstract]2025 Feb;44(3):824-853. PMID: 39707025 -
JCI Insight
Targeting HuR-Vav3 mRNA interaction prevents Pseudomonas aeruginosa adhesion to the cystic fibrosis airway epithelium. [Abstract]2023 Feb 8;8(3):e161961. PMID: 36602863 -
RSC Adv
An approach for the systematic profiling of drug-induced remodeling of RNA-RBP (RNA-binding protein) interactions. [Abstract]2026 May 19;16(29):27057-27068. PMID: 42170088 -
bioRxiv
2026 Apr 9:2026.04.07.716919. PMID: 41993498
용액&용해도
In Vitro:
DMSO : 50 mg/mL (217.18 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
N-Methylpyrrolidone (NMP) : 20 mg/mL (86.87 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2 mg/mL (8.69 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2 mg/mL (8.69 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: Corn Oil
Solubility: 5 mg/mL (21.72 mM); Suspended solution; Need ultrasonic
Add each solvent one by one: 10% NMP 90% PBS
Solubility: 2 mg/mL (8.69 mM); Suspended solution; Need ultrasonic and warming and heat to 50°C
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Human pluripotent stem cell endothelial-cell differentiation
Human pluripotent stem cell endothelial differentiation is based on stepwise developmental patterning: early activation of WNT/GSK3β inhibition promotes mesodermal or vascular progenitor entry, followed by endothelial specification using VEGF-related signaling, BMP4, FGF2, Notch modulation, or cAMP depending on the published protocol. Endothelial differentiation is read out by acquisition of CD31, CD34, VE-cadherin/CD144, KDR/VEGFR2, vWF, Tie2, NOS3, acetylated LDL uptake, tube/network formation, barrier function, and in vivo vessel-forming capacity where tested.
-
Vascular/Branching Fractal Analysis
Vascular/branching fractal analysis quantifies the geometric complexity of vessel trees or vascular networks from segmented 2D images, commonly by converting vessels into binary and/or skeletonized maps and estimating fractal dimension using box-counting or related approaches. Fractal dimension is interpreted as an image-derived readout of vascular branching complexity, space filling, or density, and has been applied to retinal photographs, fluorescein angiography, OCT angiography, capillary perfusion maps, and in vitro Matrigel angiogenesis networks. The assay readout is generated from vessel-positive pixels after image preprocessing, vessel segmentation, binarization, and optional skeletonization; reported outputs include fractal dimension, vessel density, branchpoint density, endpoint density, vessel length density, tortuosity, and generation-based branching metrics when VESGEN-style analysis is used. The biological interpretation is limited to quantitative vascular patterning and s
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Somatic Cell Culture
A method of simulating the in vivo environment in vitro to maintain the cell growth, differentation and main functions.
-
Research Protocol for Microbiome Analysis
Microbiome analysis characterizes microbial communities in biological or environmental samples by measuring community composition, diversity, taxonomic structure, functional potential, and associations with host or environmental phenotypes. 16S rRNA gene amplicon sequencing is commonly used for bacterial and archaeal taxonomic profiling, while shotgun metagenomics provides higher taxonomic resolution and direct functional information, including microbial genes, pathways, viruses, fungi, and antimicrobial-resistance genes when sequencing depth and host-DNA contamination are adequately controlled. Microbiome results are strongly affected by sample collection, storage, DNA extraction, contamination, sequencing method, reference database, and bioinformatic pipeline; therefore, standardized protocols, negative controls, mock communities, and transparent analysis workflows are required. Unresolved issues include low-biomass contamination, compositional-data bias, inconsistent species-level c
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
Cell Counting-Based Growth Curve Assay
Cell counting-based growth curve assays quantify cell proliferation by directly measuring changes in viable cell number over time using manual or automated counting methods such as hemocytometer-based counting or instrument-assisted cell enumeration, enabling construction of growth curves that reflect population expansion dynamics in response to culture conditions. A widely used approach is trypan blue exclusion with hemocytometer counting, where membrane-compromised (non-viable) cells take up the dye, allowing discrimination between viable and non-viable cells while simultaneously enabling total cell number quantification. Repeated sampling across time points allows estimation of proliferation rate, growth phases, and comparative growth kinetics between experimental conditions.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
How to Select the Route of Administration for Mammals
Route-of-administration selection in mammals is a pharmacokinetic, pharmacodynamic, formulation, animal-welfare, and translational decision, not a default technical choice. The selected route should match the study goal: intravenous dosing is most useful when complete systemic exposure and rapid onset are required, oral dosing is most translational for orally intended medicines but is affected by absorption and first-pass metabolism, subcutaneous or intramuscular dosing can provide slower systemic exposure, and intraperitoneal dosing can be useful in rodent proof-of-concept studies but may have limited clinical translation. Published route-comparison studies show that the same compound can produce different exposure, onset, bioavailability, tissue distribution, and tolerability depending on route; therefore, route choice should be supported by pilot pharmacokinetic or pharmacodynamic evidence when the literature is insufficient. Unresolved questions include how to standardize route sel
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Protocol for Cell Counting and Cell Density Analysis
Cell counting and cell-density analysis estimate the number of cells in a known volume or field area. Manual hemocytometer counting uses a chamber of defined geometry to convert counted cells into cells/mL, while automated counters and image-analysis workflows detect cell objects from optical, brightfield, fluorescence, impedance, or digital-image features. Trypan blue viability counting is based on dye exclusion: viable cells with intact membranes exclude dye, while non-viable cells with compromised membranes stain blue. The readout is total cell density, viable-cell density, dead-cell density, and percent viability. Cell density can also be estimated from microscopy images by counting objects per image area, from flow cytometry using calibrated volume or reference particles, or from in situ microscopy in bioreactors after calibration against reference methods such as hemocytometer or flow cytometry.
-
DSS-Induced Colitis
Dextran sulfate sodium (DSS)-induced colitis is generated by administering DSS in mouse drinking water, producing epithelial injury, barrier disruption, weight loss, diarrhea, fecal blood, colon shortening, histologic mucosal damage, and inflammatory mediator changes; the model is mainly used to study acute or chronic intestinal inflammation resembling selected features of ulcerative colitis. DSS injury is interpreted through clinical and tissue readouts rather than a single molecular endpoint: daily body weight, stool consistency, and bleeding are combined into a disease activity index, while colon length, histology, cytokines, myeloperoxidase activity, intestinal permeability, and tight-junction markers provide complementary measures of inflammation and barrier damage.
-
TNBS-Induced Colitis
TNBS-induced colitis is produced by intrarectal delivery of 2,4,6-trinitrobenzene sulfonic acid in ethanol, where ethanol disrupts the mucosal barrier and TNBS haptenates colonic proteins, generating immune-mediated colonic inflammation with weight loss, diarrhea, ulceration, transmural injury, inflammatory-cell infiltration, and cytokine responses. The model is used as an experimental intestinal inflammation model with Crohn’s disease–like features, especially when Th1-type responses, IL-12–dependent inflammation, chronic relapsing inflammation, or fibrosis-related endpoints are studied.
-
Endothelial Tube Formation Assay
Endothelial tube formation assay evaluates the ability of endothelial cells to attach, migrate, align, and organize into capillary-like networks when cultured on gelled basement membrane extract or Matrigel; the readout is the morphology and quantity of tube-like networks, which reflects an in vitro endothelial morphogenesis step related to angiogenesis. Basement membrane extract/Matrigel provides laminin-rich extracellular matrix cues that support endothelial differentiation into capillary-like structures, but it can contain biologically active growth factors, so growth-factor-reduced matrix is preferred when testing defined angiogenic stimulators or inhibitors.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Cell invasion
Cell invasion is the ability of cells to migrate from one area to another via the extracellular matrix. Cell invasion is the response of normal and cancer cells to chemical and mechanical stimuli. Before migrating to a new region, the extracellular matrix is degraded by proteases within the cell. Cell invasion often occurs during wound repair, vascularization and inflammation, abnormal tissue invasion, and tumor cell metastasis.
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
-
Endothelial Cell Migration/Angiogenic Sprouting Assay
Endothelial cell migration and angiogenic sprouting assays are in vitro (and partially ex vivo-adapted) functional models that quantify the ability of endothelial cells to undergo coordinated migration, extracellular matrix invasion, and multicellular organization into capillary-like sprouts in response to pro-angiogenic stimuli such as VEGF, bFGF, or conditioned microenvironments. These assays are used to model early angiogenic events including tip-cell formation, directional migration, and lumen-like sprout extension, which collectively reflect angiogenic activation and vascular morphogenesis processes observed in vivo.
순도&문서
-
Data Sheet (290 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Blanco FF, et al. Impact of HuR inhibition by the small molecule MS-444 on colorectal cancer cell tumorigenesis. Oncotarget. 2016;7(45):74043-74058. [Content Brief]
[2]. Lang M, et al. HuR Small-Molecule Inhibitor Elicits Differential Effects in Adenomatosis Polyposis and Colorectal Carcinogenesis. Cancer Res. 2017;77(9):2424-2438. [Content Brief]
[3]. Wang J, et al. Anti-cancer effects of the HuR inhibitor, MS-444, in malignant glioma cells. Cancer Biol Ther. 2019;20(7):979-988. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| N-Methylpyrrolidone (NMP) / DMSO | 1 mM | 4.3437 mL | 21.7184 mL | 43.4367 mL | 108.5918 mL |
| 5 mM | 0.8687 mL | 4.3437 mL | 8.6873 mL | 21.7184 mL | |
| 10 mM | 0.4344 mL | 2.1718 mL | 4.3437 mL | 10.8592 mL | |
| 15 mM | 0.2896 mL | 1.4479 mL | 2.8958 mL | 7.2395 mL | |
| 20 mM | 0.2172 mL | 1.0859 mL | 2.1718 mL | 5.4296 mL | |
| 25 mM | 0.1737 mL | 0.8687 mL | 1.7375 mL | 4.3437 mL | |
| 30 mM | 0.1448 mL | 0.7239 mL | 1.4479 mL | 3.6197 mL | |
| 40 mM | 0.1086 mL | 0.5430 mL | 1.0859 mL | 2.7148 mL | |
| 50 mM | 0.0869 mL | 0.4344 mL | 0.8687 mL | 2.1718 mL | |
| 60 mM | 0.0724 mL | 0.3620 mL | 0.7239 mL | 1.8099 mL | |
| 80 mM | 0.0543 mL | 0.2715 mL | 0.5430 mL | 1.3574 mL | |
| DMSO | 100 mM | 0.0434 mL | 0.2172 mL | 0.4344 mL | 1.0859 mL |